Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).

Seminars in cancer biology - 1 Aug 2017

Smith C I Edvard

Abstract excerpt

Darwinian selection is also applicable when antibiotics, the immune system or other host factors shape the repertoire of microorganisms, and similarly, clonal selection is the hallmark of tumor evolution. The ongoing revolution in new anti-cancer treatment modalities, combined with an unprecedented precision in characterizing malignant clones at the level below one percent, profoundly improves the understanding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Transformation, Neoplastic
Share to Clonal Evolution

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Genetic Fitness

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Source

Identifiers

PMID: 27865897
DOI: 10.1016/j.semcancer.2016.11.008

Genes

ALK
BCR
BRAF
BTK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).PMID 27865897Read ↗

Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure.Semantic proximity Read ↗

Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapySemantic proximity Read ↗

Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.Semantic proximity Read ↗

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.Semantic proximity Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

Nothing makes sense in drug resistance except in the light of evolutionSemantic proximity Read ↗

Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer.Semantic proximity Read ↗

Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.Semantic proximity Read ↗

Identifying and Targeting the Cause of Cancer is Needed to Cure CancerSemantic proximity Read ↗

Mechanisms and insights into drug resistance in cancerSemantic proximity Read ↗

Drug Resistance in Cancers: A Free Pass for BullyingSemantic proximity Read ↗

Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.